Literature DB >> 1943688

Alcaptonuria and ochronotic arthritis.

B N La Du1.   

Abstract

The rare hereditary metabolic disorder alcaptonuria is characterized by the inability to metabolize homogentisic acid, an intermediary compound in the catabolism of the aromatic amino acids phenylalanine and tyrosine. The essentially complete deficiency of homogentisic acid oxidase causes a striking accumulation of homogentisic acid and a derived melanin-like pigment in the connective tissues; the latter is termed ochronosis. Urinary homogentisic acid is oxidized rapidly and becomes a brown or black pigment if alkali is added. Older alcaptonurics have intensely pigmented (ochronotic) connective tissues, primarily the cartilaginous joint surfaces, ribs, intervertebral disks, ear cartilage, etc. They also have an unusual type of arthritis affecting the large weight-bearing joints, i.e. hips, knees and spine, but not the small joints of the hands and feet, as in rheumatoid arthritis. A mechanistic explanation for ochronotic arthritis has not been worked out, but it is clear that accumulation of homogentisic acid in the connective tissues directly or indirectly leads to the arthritic changes. A detailed analysis of the events leading to alcaptonuric arthritis should be worthwhile since it is a model form of arthritis secondary to a well-defined metabolic disorder that must persist for many years before the arthritic complications appear. Possibly other, more common types of arthritis, develop secondarily to metabolic disturbances that involve chemical mediators less obvious, or less easily detected, than homogentisic acid.

Entities:  

Mesh:

Year:  1991        PMID: 1943688

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  10 in total

1.  A black femoral head.

Authors:  Enrico Selvi; Roberta Maggio; Estrella Garcia Gonzalez; Marco Bardelli
Journal:  BMJ Case Rep       Date:  2009-02-26

Review 2.  Inborn errors of metabolism: Garrod's legacy.

Authors:  A G Bearn
Journal:  Mol Med       Date:  1996-05       Impact factor: 6.354

Review 3.  [Severe osteoarthritic manifestations of ochronosis].

Authors:  U Lange; U Müller-Ladner; G Dischereit
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

4.  Detection of alkaptonuria in a 1-week-old infant.

Authors:  Krishan Nilantha Hewa Thalagahage; Jayaweera Arachchige Asela Sampath Jayaweera; Wikum Widuranga Kumbukgolla; Indika Senavirathne
Journal:  BMJ Case Rep       Date:  2015-05-08

Review 5.  Arthroscopic treatment of shoulder ochronotic arthropathy: a case report and review of literature.

Authors:  A Castagna; A Giombini; G Vinanti; G Massazza; F Pigozzi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2005-08-03       Impact factor: 4.342

6.  Role of melanin pigment in expression of Vibrio cholerae virulence factors.

Authors:  Soni Priya Valeru; Pramod Kumar Rompikuntal; Takahiko Ishikawa; Karolis Vaitkevicius; Asa Sjöling; Nadia Dolganov; Jun Zhu; Gary Schoolnik; Sun Nyunt Wai
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

7.  Biochemical and proteomic characterization of alkaptonuric chondrocytes.

Authors:  Daniela Braconi; Giulia Bernardini; Claretta Bianchini; Marcella Laschi; Lia Millucci; Loredana Amato; Laura Tinti; Tommaso Serchi; Federico Chellini; Adriano Spreafico; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

8.  Ochronotic Surprise during Total Knee Replacement! A Case Report.

Authors:  Syam G; John Thayyil John; Dileep Sasidharan Nair; Shikhar Yadav; Joice Varghese; Jamsheed T
Journal:  J Orthop Case Rep       Date:  2021-10

9.  Knee osteoarthrosis secondary to ochronosis - clinical case.

Authors:  Andreia Maria da Silva Martins Ferreira; Filipe Lima Santos; André Miguel Castro Costa; Bruno Miguel Pereira Barbosa; Rui Miguel Reis Rocha; Joaquim Fernando Fontes Lebre
Journal:  Rev Bras Ortop       Date:  2014-10-27

10.  Black hip: a rare case treated by total hip replacement.

Authors:  Narayana Gowda; Mohan J Kumar; Ajith K Kumar
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.